174 related articles for article (PubMed ID: 35400525)
1. Germline BRCA variants, lifestyle and ovarian cancer survival.
Gersekowski K; Delahunty R; Alsop K; Goode EL; Cunningham JM; Winham SJ; Pharoah P; Song H; Jordan S; Fereday S; DeFazio A; Friedlander M; Obermair A; ; ; Webb PM
Gynecol Oncol; 2022 Jun; 165(3):437-445. PubMed ID: 35400525
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
Heemskerk-Gerritsen BAM; Hollestelle A; van Asperen CJ; van den Beek I; van Driel WJ; van Engelen K; Gómez Garcia EB; de Hullu JA; Koudijs MJ; Mourits MJE; Hooning MJ; Boere IA
PLoS One; 2022; 17(9):e0275015. PubMed ID: 36137114
[TBL] [Abstract][Full Text] [Related]
4. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 germline mutations may be associated with reduced ovarian reserve.
Wang ET; Pisarska MD; Bresee C; Chen YD; Lester J; Afshar Y; Alexander C; Karlan BY
Fertil Steril; 2014 Dec; 102(6):1723-8. PubMed ID: 25256924
[TBL] [Abstract][Full Text] [Related]
6. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
8. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Bolton KL; Chenevix-Trench G; Goh C; Sadetzki S; Ramus SJ; Karlan BY; Lambrechts D; Despierre E; Barrowdale D; McGuffog L; Healey S; Easton DF; Sinilnikova O; Benítez J; García MJ; Neuhausen S; Gail MH; Hartge P; Peock S; Frost D; Evans DG; Eeles R; Godwin AK; Daly MB; Kwong A; Ma ES; Lázaro C; Blanco I; Montagna M; D'Andrea E; Nicoletto MO; Johnatty SE; Kjær SK; Jensen A; Høgdall E; Goode EL; Fridley BL; Loud JT; Greene MH; Mai PL; Chetrit A; Lubin F; Hirsh-Yechezkel G; Glendon G; Andrulis IL; Toland AE; Senter L; Gore ME; Gourley C; Michie CO; Song H; Tyrer J; Whittemore AS; McGuire V; Sieh W; Kristoffersson U; Olsson H; Borg Å; Levine DA; Steele L; Beattie MS; Chan S; Nussbaum RL; Moysich KB; Gross J; Cass I; Walsh C; Li AJ; Leuchter R; Gordon O; Garcia-Closas M; Gayther SA; Chanock SJ; Antoniou AC; Pharoah PD; ; ;
JAMA; 2012 Jan; 307(4):382-90. PubMed ID: 22274685
[TBL] [Abstract][Full Text] [Related]
9. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
Stasenko M; Cybulska P; Feit N; Makker V; Konner J; O'Cearbhaill RE; Alektiar KM; Beal K; Gardner GJ; Long Roche KC; Sonoda Y; Chi DS; Zivanovic O; Leitao MM; Cadoo KA; Tew WP
Gynecol Oncol; 2019 Jul; 154(1):144-149. PubMed ID: 31113680
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis.
Gersekowski K; Na R; Alsop K; Delahunty R; Goode EL; Cunningham JM; Winham SJ; Pharoah PDP; Song H; Webb PM
Cancer Epidemiol Biomarkers Prev; 2024 Apr; 33(4):586-592. PubMed ID: 38300121
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
12. The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
Ko KP; Kim SJ; Huzarski T; Gronwald J; Lubinski J; Lynch HT; Armel S; Park SK; Karlan B; Singer CF; Neuhausen SL; Narod SA; Kotsopoulos J;
Int J Cancer; 2018 Jun; 142(11):2263-2272. PubMed ID: 29330845
[TBL] [Abstract][Full Text] [Related]
13. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
14. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
[TBL] [Abstract][Full Text] [Related]
15. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
Lavie O; Chetrit A; Novikov I; Sadetzki S;
Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026
[TBL] [Abstract][Full Text] [Related]
16. Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis.
Grill S; Yahiaoui-Doktor M; Dukatz R; Lammert J; Ullrich M; Engel C; Pfeifer K; Basrai M; Siniatchkin M; Schmidt T; Weisser B; Rhiem K; Ditsch N; Schmutzler R; Bischoff SC; Halle M; Kiechle M
Arch Gynecol Obstet; 2017 Dec; 296(6):1135-1144. PubMed ID: 28975393
[TBL] [Abstract][Full Text] [Related]
17. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
18. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
20. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
